References
- WHO: chronic rheumatic conditions [internet]. WHO. cited 2008 Jan 20. Available from: www.who.int/chp/topics/rheumatic/en/
- Dos Santos JBR, Almeida AM, Acurcio FA, et al. Comparative effectiveness of adalimumab and etanercept for rheumatoid arthritis in the Brazilian Public Health System. J Comp Eff Res. 2016;5(6):539–549.
- Puchner R, Hochreiter R, Pieringer H, et al. Improving patient flow of people with rheumatoid arthritis has the potential to simultaneously improve health outcomes and reduce direct costs. BMC Musculoskelet Disord. 2017;18(1):7–14.
- Tundia N, Kotze PG, Serrano JR, et al. Economic impact of expanded use of biologic therapy for the treatment of rheumatoid arthritis and Crohn’s disease in Argentina, Brazil, Colombia and Mexico. J Med Econ. 2016;19(12):1187–1199.
- Global rheumatoid arthritis drugs market. iHealthcareAnalyst [internet]. 2016 April 8. [cited 2018 Jan 5]. Available from: https://www.ihealthcareanalyst.com/global-rheumatoid-arthritis-drugs-market/
- Laev SS, Salakhutdinov NF. Anti-arthritic agents: progress and potential. Bioorg Med Chem. 2015;23(13):3059–3080.
- Almeida SCL, Joaquim LF, Schwartzmann PV, et al. Assessment of patients with arthritis. Medicina (Ribeirão Preto). 2010;43(3):283–291. Available from: http://www.revistas.usp.br/rmrp/article/view/185
- Zampeli E, Vlachoyiannopoulos PG, Tzioufas AG. Treatment of rheumatoid arthritis: unraveling the conundrum. J Autoimmun. 2015;65:1–18.
- Calabrò A, Caterino AL, Elefante E, et al. One year in review 2016: novelties in the treatment of rheumatoid arthritis. Clin Exp Rheumatol. 2016;34(3):357–372.
- Agarwal SK. Biologic agents in rheumatoid arthritis: an update for managed care professionals. J Manag Care Pharm. 2011;17(9–b):S14–S18.
- Sharma P, Pathak K. Are biological targets the final goal for rheumatoid arthritis therapy? Expert Opin Biol Ther. 2012;12(12):1611–1622.
- Singh JA, Saag KG, Bridges SL Jr, et al. 2015 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Rheumatol. 2016;68(1):1–26.
- Myrick ER, William PS, Ram N. Technological innovation process: patent documentation as a source of technological information. Santa Clara High Tech L J. 1993;9(1):355–378.
- OECD Patent Statistics Manual – 2009 – [internet]. Organisation for Economic Co-operation and Development. [cited 2018 Mar 11]. Available from: http://www.oecd.org/sti/inno/oecdpatentstatisticsmanual.htm
- Roche Pharmaceutical Business Overview [internet]. F. Hoffmann-La Roche Ltd. [cited 2018 mar 11]. Available from: http://www.roche.com/about/business/pharmaceuticals/roche_pharmaceuticals_business_overview.html
- Sankowski AJ, Łebkowska UM, Ćwikła J, et al. Psoriatic arthritis. Pol J Radiol. 2013;78(1):7–17.
- Mayo Clinic. Psoriatic Arthiritis [internet]. Mayo Foundation for Medical Education and Research (MFMER). [cited 2018 July 12]. Available from: https://www.mayoclinic.org/diseases-conditions/psoriatic-arthritis/symptoms-causes/syc-20354076
- Arthritis Foundation: types of Arthritis [internet]. Atlanta (GA): Arthritis Foundation National Office. [cited 2018 Mar 11]. Available from: http://www.arthritis.org/about-arthritis/types/
- Gavrilă BI, Ciofu C, Stoica V. Biomarkers in rheumatoid arthritis, what is new? J Med Life. 2016;9(2):144–148.
- Mirich J. Genqual Corp and Mirich Jonatan, assignee. Methods of prognosing and administering treatment for inflammatory disorders. 2012 Aug 16. WO2012109427.
- Glyn JRD, Martin F, Townsend MJ, inventors. F. Hoffmann-La Roche AG + Genentech Inc, assignees. Methods for treating, diagnosing, and monitoring rheumatoid arthritis. 2012 May 10. WO2012061620.
- Siebert S, Tsoukas A, Robertson J, et al. Cytokines as therapeutic targets in rheumatoid arthritis and other inflammatory diseases. Pharmacol Rev. 2015;67(2):280–309.
- Guo H, Li C, Tong X, inventors. Biomab Pharmaceuticals Ltd, assignee. Full human anti-TNF-alpha monoclonal antibody, preparation method and use thereof. 2011 Sep 11. WO2011103701.
- Padley RJ, Heuser R, inventors. AbbVie Inc, assignee. Compositions and methods for treating rheumatoid arthritis. 2015 Sep 15. WO2015138337.
- Burmester GR, Feist E, Dörner T. Emerging cell and cytokine targets in rheumatoid arthritis. Nat Rev Rheumatol. 2014;77–88.
- Martin JH, Wang L-H, Stevens S, et al. inventors. Regeneron Pharmaceuticals Inc, assignee. Human antibodies to human CD20 and method of using thereof. US2011081681; 2011 Apr 07.
- Damle NK, Tchistiakova L, Danussi-Joannopoulos K, et al., inventors. Wyeth LLC + Emergent BioSolutions Inc, assignees. Anti-CD20 therapeutic compositions and methods. 2008 Dec 24. WO2008156713.
- Misher LE, Lofquist AK, inventors. Emergent Product Development Seattle LLC, assignee. Compositions comprising TNF-alpha and IL-6 antagonists and methods of use thereof. 2011 Jun 30. WO2011079308.
- Wilkins JA, Oshodi SA, Lobo B, et al., inventors. Genentech Inc, assignee. Crystallization of anti-CD20 antibodies. 2009 Jul 09. WO2009085765.
- Thomson Reuters Integrity FAQs [internet]. Clarivate Analytics. Brazil. 2017. [cited 2017 Oct 3]. Available from: https://integrity.thomson-pharma.com/igrcontent/pdf/faqs.pdf
- Brodniewicz T, Grynkiewicz G. Preclinical drug development. Acta Pol Pharm. 2010;67(6):578–585.
- Cuff C, Caldwell R, Heuser R, et al., inventors. Abbvie Inc, assignee. Compositions and methods for treating rheumatoid arthritis. 2015 Dec 17. WO2015191760.
- About Abbvie. North Chicago, Illinois, U.S.A: Abbvie, Inc. 2018. [cited 2017 Oct 3]. Available from: https://www.abbvie.com/our-company/about-abbvie.html
- Fernandez JE, Dixon DA, Paulson A, inventors. Ablynx N.v, Wyeth Llc, assignees. Formulations of single domain antigen binding molecules. 2016 Sep 15. US2016263220.
- Won HS, Sung BJ, Ahn YH, et al., inventors. Hanwha Chemical Corp, assignee. Method for preparing active form of TNFR-Fc fusion protein. 2013 Feb 21. WO2013025079.
- Integrity database: products list [internet]. Clarivate Analytics. 2018. [cited 2017 Oct 3]. Available from: https://integrity.thomson-pharma.com/integrity/xmlxsl/
- Behrens TW, Owczarczyk K, Townsend MJ, inventors. Genentech Inc, Hoffmann La Roche, assignees. Biological markers and methods for predicting response to B-cell antagonists. Sep; 2012. p. 07. WO2012118750.
- Genentech, About us. Genentech, Inc. 2018. [cited 2017 Oct 3]. Available from: https://www.gene.com/about-us
- Morad R. Top 10 Best-Selling Biotech Drugs 2014. BioSpace.com. 2015. [cited 2018 Jan 5]. Available from: http://www.biospace.com/News/top-10-best-selling-biotech-drugs/393360
- Covic A, Kuhlmann MK. Biosimilars: recent developments. Int Urol Nephrol. 2007;39(1):261–266.
- Salata OV. Applications of nanoparticles in biology and medicine. J Nanobiotechnol. 2004;2:3.